CA2635269A1 - Adipogenic adenoviruses as a biomarker for disease - Google Patents

Adipogenic adenoviruses as a biomarker for disease Download PDF

Info

Publication number
CA2635269A1
CA2635269A1 CA002635269A CA2635269A CA2635269A1 CA 2635269 A1 CA2635269 A1 CA 2635269A1 CA 002635269 A CA002635269 A CA 002635269A CA 2635269 A CA2635269 A CA 2635269A CA 2635269 A1 CA2635269 A1 CA 2635269A1
Authority
CA
Canada
Prior art keywords
adenovirus
subject
adipogenic
sample
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002635269A
Other languages
English (en)
French (fr)
Inventor
Richard L. Atkinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Obetech LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2635269A1 publication Critical patent/CA2635269A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
CA002635269A 2005-12-27 2006-12-27 Adipogenic adenoviruses as a biomarker for disease Abandoned CA2635269A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75340205P 2005-12-27 2005-12-27
US60/753,402 2005-12-27
PCT/US2006/062632 WO2007120362A2 (en) 2005-12-27 2006-12-27 Adipogenic adenoviruses as a biomarker for disease

Publications (1)

Publication Number Publication Date
CA2635269A1 true CA2635269A1 (en) 2007-10-25

Family

ID=38610014

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002635269A Abandoned CA2635269A1 (en) 2005-12-27 2006-12-27 Adipogenic adenoviruses as a biomarker for disease

Country Status (11)

Country Link
US (5) US7442511B2 (https=)
EP (2) EP1977009B1 (https=)
JP (1) JP2009521707A (https=)
KR (1) KR20080114683A (https=)
CN (1) CN101389768B (https=)
AU (1) AU2006342053A1 (https=)
BR (1) BRPI0620755A2 (https=)
CA (1) CA2635269A1 (https=)
MX (1) MX2008008453A (https=)
RU (1) RU2008130893A (https=)
WO (1) WO2007120362A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507418B2 (en) * 2005-09-09 2009-03-24 Obetech, Llc Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes
US7442511B2 (en) * 2005-12-27 2008-10-28 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
JP2009156254A (ja) * 2007-12-05 2009-07-16 Ibiden Co Ltd 排気ガス処理体の保持シール部材及び排気ガス処理装置
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
WO2010011440A2 (en) * 2008-06-16 2010-01-28 Obetech Llc Diagnosis and treatment of lipogenic adenovirus infection associated with adipose tissue hypertrophy
JP5867952B2 (ja) 2009-06-10 2016-02-24 ノバルティス アーゲー ベンゾナフチリジン含有ワクチン
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
WO2011050299A2 (en) * 2009-10-22 2011-04-28 Obetech Llc Adenovirus infection in animals
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
US8591412B2 (en) * 2009-11-18 2013-11-26 Nohands, Llc Method and system for preventing virus-related obesity and obesity related diseases
BR112012014624A8 (pt) 2009-12-15 2017-12-26 Novartis Ag suspensão homogênea de compostos de imunopotenciação e usos dos destes
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
WO2011119915A2 (en) * 2010-03-25 2011-09-29 Obetech Llc Method for detecting lipogenic adenovirus
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
US8951980B2 (en) * 2010-07-08 2015-02-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Adenovirus Ad36 E4 orf1 protein for prevention and treatment of non-alcoholic fatty liver disease
WO2012006550A2 (en) * 2010-07-09 2012-01-12 Obetech Llc Methods and compositions for treatment of lipogenic virus related conditions
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
BR112015018014A2 (pt) 2013-02-01 2017-07-11 Glaxosmithkline Biologicals Sa liberação intradérmica de composições imunológicas compreendendo agonistas do receptor do tipo toll
US9925254B2 (en) 2014-11-05 2018-03-27 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against Campylobacter jejuni
JP7362667B2 (ja) 2018-02-12 2023-10-17 イニミューン・コーポレーション Ｔｏｌｌ様受容体リガンド
AU2019352906B2 (en) * 2018-10-05 2026-01-22 Minomic International Ltd. Biomarker combinations for determining aggressive prostate cancer
JP2023547677A (ja) 2020-11-04 2023-11-13 エリゴ・バイオサイエンス キューティバクテリウム・アクネス組換えファージ、その産生方法及び使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU692152B2 (en) * 1993-03-17 1998-06-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
AU6884298A (en) * 1997-04-04 1998-10-30 Obetech, Llc Viral obesity methods and compositions
JP2000072800A (ja) * 1998-08-26 2000-03-07 Toagosei Co Ltd 抗アデノウイルス３７型モノクローナル抗体及びその用途
CA2632013C (en) * 2005-11-30 2013-02-26 Wayne State University Adenovirus 36 e4 orf 1 gene and protein and their uses
US7442511B2 (en) * 2005-12-27 2008-10-28 Obetech, Llc Adipogenic adenoviruses as a biomarker for disease

Also Published As

Publication number Publication date
US7442511B2 (en) 2008-10-28
US7910310B2 (en) 2011-03-22
CN101389768A (zh) 2009-03-18
US7745110B2 (en) 2010-06-29
KR20080114683A (ko) 2008-12-31
EP1977009A2 (en) 2008-10-08
RU2008130893A (ru) 2010-02-10
WO2007120362A3 (en) 2008-08-14
BRPI0620755A2 (pt) 2011-11-22
WO2007120362A2 (en) 2007-10-25
US20070218081A1 (en) 2007-09-20
US20090087833A1 (en) 2009-04-02
US20090087455A1 (en) 2009-04-02
US20110189235A1 (en) 2011-08-04
EP1977009B1 (en) 2016-08-17
US20130323273A1 (en) 2013-12-05
AU2006342053A1 (en) 2007-10-25
JP2009521707A (ja) 2009-06-04
EP1977009A4 (en) 2009-06-03
CN101389768B (zh) 2015-11-25
EP2390372A1 (en) 2011-11-30
MX2008008453A (es) 2008-11-28

Similar Documents

Publication Publication Date Title
CA2635269A1 (en) Adipogenic adenoviruses as a biomarker for disease
Filmus et al. Glypican‐3: a marker and a therapeutic target in hepatocellular carcinoma
CN102171570B (zh) 用于检测癌的方法
JP4917207B2 (ja) 前立腺疾患の検出に有用な試薬及び方法
KR101872965B1 (ko) Ｃ―ｍａｆ를 이용하는 전립선암 전이의 진단, 예후 및 치료 방법
EP2853898B1 (en) Analysis of myostatin in serum
JP2010246558A (ja) 乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法
JP2011092195A (ja) 卵巣癌の同定、評価、予防および治療のための核酸分子およびタンパク質
JP2006201187A (ja) 前立腺ガンの免疫診断のための化合物およびそれらの使用方法
PT1994410E (pt) Métodos e estojos para detecção precoce de cancro ou de predisposição a este
JP2009544284A5 (https=)
JP2008509673A (ja) ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法
CN113667748A (zh) circIKBKB的抑制剂及其检测试剂在乳腺癌骨转移诊断、治疗和预后试剂盒的应用
JP2001521744A (ja) 乳房の疾患の検出に有用な試薬および方法
CN109517898B (zh) 一种食管癌检测、诊断或者预后评价制剂，治疗食管癌的药物及rnd2基因的应用
JP2001522238A (ja) 胃腸管の疾患の検出に有用な試薬および方法
JP2012509683A (ja) 膵癌のバイオマーカーとしてのｃｘｃｌ４ｌ１
JP2012513584A5 (https=)
KR102180982B1 (ko) 갑상선암 진단 또는 예후 예측용 adm2 유전자 마커 및 이의 용도
JP2002503956A (ja) 前立腺の疾患の検出に有用な試薬および方法
WO2006098074A1 (ja) 前立腺癌細胞のアポトーシス誘発剤
KR20220020538A (ko) 전립선암 진단용 마커
CN102778566A (zh) Dlk1在肝癌诊断及预后判断中的应用
JP2022521535A (ja) 前立腺がんのバイオマーカとしてのｂｍｍｆ１ ｒｅｐタンパク質の使用
KR101314959B1 (ko) 결장직장선종 및/또는 결장직장암종에 대한 생체표지로서엔도플라스민 단편 및 그 유도체의 사용； 검출 방법 및시험 시스템

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20171228